Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (June 2018)
24 slides from Harrow's investor presentation, Jun 1, 2018
Slide 1: At an Inflection Point
At an Inflection Point imprimi PHARMACEUTICALS NASDAQ: IMMY JUNE 2018
Slide 2: Safe Harbor
SAFE HARBOR! This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assum
Slide 3: Pharmaceutical company with 60+ formulation patent filings
Pharmaceutical company with 60+ formulation composition and method of use patent filings 153% CAGR during first four years of operations, with record sequential growth (in dollar amount) in most recent quarterly period Incubated and deconsolidated two subsidiary companies based on IP portfolio; purs
Slide 4: Imprimis Owns
@ IMPRIMIS OWNS: @ IMPHIMIS Pp PARK . COMPOUNDING Imprimis primis IMPRIMIS IS A LARGE SHAREHOLDER ® ACG Gurface M e ELT
Slide 5: Consolidated Revenue Performance
@ CONSOLIDATED REVENUE PERFORMANCE (IN THOUSANDS) Trends: 16 consecutive quarters of double digit revenue growth Margins expected to hit 60% Decreasing Adj. EBITDA losses Increasing share of business is focused on ophthalmic drugs $7,000 = Ophthalmology Sales (ImprimisRx) HINon-Ophthalmology Sales (
Slide 6: Imprimis Ophthalmology
._.IMPFIMIs g. [OPHTHALMOLOGY
Slide 7: Physician and Institution Benefits
imprimis FEE] Heat B88] PHYSICIAN AND INSTITUTION In most states, physicians can dispense direct to patient BENEFITS No insurance company, pharmacy benefit manager (PBM), wholesaler or distributor middlemen No formulary rejections, discount cards or rebates No payment submittals, investigations or P
Slide 8: Ophthalmology Market Data
OPHTHALMOLOGY MARKET DATA @ OPHTHALMIC SURGERY @ GLAUCOMA @ DRY EYE OPPORTUNITY IN US $1 billion drug market ~4.6M ocular surgeries and other procedures*-* Demographic growth in the overall market ~6% per yr'® $2 billion drug market 19+ million targeted prescriptions? 4 million Americans'® $2 billio
Slide 9: Formulations for Individual Patients: Simple Drops
FORMULATIONS FOR INDIVIDUAL PATIENTS: SIMPLE DROPS™ Imprimiss, Some a Latanoprost (PA) — preservative-free Timolol (BB) + latanoprost (PA) Timolol (BB) + brimonidine (AA) + dorzolamide (CAl) Timolol (BB) + brimonidine (AA) + dorzolamide (CAl) + latanoprost (PA) PROPRIETARY FORMULATIONS INCLUDE: FROM
Slide 10: Formulations for Individual Patient: Dry Eye
FORMULATIONS FOR INDIVIDUAL PATIENT: PROPRIETARY FORMULATIONS INCLUDE: Chondroitin sulfate + 0.1% cyclosporine Omega-3 AR Omega-3 AR/Doxycycline Klarity (chondroitin sulfate + dextran) TOTALTEARS™ FROM THE MEDICAL LITERATURE: * Ocular burning/stinging is a major cause of therapy discontinuation for
Slide 11: Formulations for Office Use
FORMULATIONS FOR OFFICE USE PROPRIETARY FORMULATIONS INCLUDE: Prednisolone acetate + gatifloxacin Prednisolone acetate + gatifloxacin + bromfenac Prednisolone acetate + bromfenac Midazolam + ketamine HCI + ondansetron PHARMAPACK™ @ OCULAR SURGERY MARKET: + ~4.6M ocular surgeries and other procedures
Slide 12: Slide 12
Slide 13: Eton Pharmaceuticals
ETON PHARMACEUTICALS, INC. DECONSOLIDATED COMPANY WHAT IS IT? WHY IS IT IMPORTANT? WHAT IS THE OPPORTUNITY? + 505(b)(2) company * Imprimis holds a 27% equity + Imprimis owns 3.5M shares of Eton developing 6 drug programs stake in Eton common stock + Deconsolidated from + Mid-single digit royalty on
Slide 14: Surface Pharmaceuticals
G@urface SURFACE PHARMACEUTICALS, INC. DECONSOLIDATED COMPANY WHAT IS IT? WHY IS IT IMPORTANT? WHAT IS THE OPPORTUNITY? + 505(b)(2) company with three + Imprimis holds a 30% equity + Imprimis owns 3.5M shares of pipeline drug assets focused stake in Surface Surface common stock on the ocular surface
Slide 15: Melt Pharmaceuticals
MELT MELT PHARMACEUTICALS, INC. SUBSIDIARY COMPANY WHAT IS IT? + Developing patented non-opioid conscious sedation drug candidates under 505(b)(2) + Very strong regulatory and clinical advisory consulting team + May pursue deconsolidation transaction similar to Eton and Surface WHY IS IT IMPORTANT?
Slide 16: Park Compounding
PARK COMPOUNDING 21% OF Q1-2018 REVENUES PARK COMPOUNDING, INC. SUBSIDIARY COMPANY WHAT IS IT? WHY IS IT IMPORTANT? WHAT IS THE OPPORTUNITY? + Wholly owned subsidiary + Large, growing and loyal + Add new products and expand + Focused on patient-specific customer base customer base customized drugs *
Slide 17: Slide 17
Slide 18: Imprimis Pharmaceuticals
Imprimis PHARMACEUTICALS IMPRIMISRX IS ONE OF THE LARGEST OPHTHALMOLOGY COMPOUNDING BUSINESSES IN THE US PRODUCTS AND MARKET SHARE GROWTH AND PROFITABILITY BALANCE SHEET VALUE FROM SUBSIDIARIES AND DECONSOLIDATED COMPANIES Disrupting US ophthalmic drug markets with novel compounded formulations + Op
Slide 19: Company Profile
COMPANY PROFILE TRADING SYMBOL: PRICE PER SHARE (5-31-2018): STOCK PRICE RANGE (52- NASDAQ: IMMY $2.23 $1.35 - $4.69 AVG. DAILY Q1 TRADING VOLUME: | MARKET CAP: SHARES OUTSTANDING: 492,000 SHARES $47 MILLION 20.9 MILLION INSIDER BENEFICIAL OWNERSHIP: | CORPORATE HEADQUARTERS: PRODUCTION FACILITIES:
Slide 20: References and Appendix
REFERENCES AND APPENDIX
Slide 21: References
@ REFERENCES 14. 15. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May) Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from https://www.statista.com/statistics/27 1478/number-of-lasik-surgeries-in-the-us/ Imprimis Pharmaceutical
Slide 22: References
@ REFERENCES 23. . Glaucoma Research Foundation. Glaucoma Facts and Stats. Retrieved February 9, 2017 from http:/www.glaucoma.org/glaucoma/facts-statistics/glaucoma-facts-and-stats.php . Schott, Chris, J.P. Morgan, “Eye’ deally Positioned to Expand the Dry Eye Market . . .” August 14, 2017 . Grover,
Slide 23: Published Clinical Data
PUBLISHED CLINICAL DATA In a study of 483 eyes undergoing cataract surgery with concomitant trabecular microbypass stent insertion, there were no statistically significant differences in the safety profiles of a study group of 234 eyes receiving an intravitreal injection (pars plana) of 0.2mL of Dro
Slide 24: EON ‘12264 EL CAMINO REAL, SUITE :
EON ‘12264 EL CAMINO REAL, SUITE : os : bod ‘* es ‘350 SAN DIEGO,.CA 92130 im A mis cou 4 IR@IMPRIMISPHARMA.COM PHARMACEUTICALS WWW.IMPRIMISRX.COM
Imprimis Pharmaceuticals — Investor Presentation (June 2018) on 6ix